Deanna A. Mele

1.9k total citations · 1 hit paper
14 papers, 1.2k citations indexed

About

Deanna A. Mele is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Deanna A. Mele has authored 14 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Immunology. Recurrent topics in Deanna A. Mele's work include Cancer Immunotherapy and Biomarkers (5 papers), Adenosine and Purinergic Signaling (3 papers) and Peptidase Inhibition and Analysis (3 papers). Deanna A. Mele is often cited by papers focused on Cancer Immunotherapy and Biomarkers (5 papers), Adenosine and Purinergic Signaling (3 papers) and Peptidase Inhibition and Analysis (3 papers). Deanna A. Mele collaborates with scholars based in United States, United Kingdom and Brazil. Deanna A. Mele's co-authors include Barbara M. Bryant, Andrew R. Conery, Louise Bergeron, Péter Sandy, Srividya Balasubramanian, Jennifer A. Mertz, Robert J. Sims, José M. Lora, Hon-Ren Huang and Srimoyee Ghosh and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Cancer Research.

In The Last Decade

Deanna A. Mele

14 papers receiving 1.2k citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting MYC dependence in cancer by inhibiting BET bromodomains

2011 876 citations Jennifer A. Mertz, Andrew R. Conery et al. Proceedings of the National Academy of Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Deanna A. Mele United States	8	1.0k	393	277	187	79	14	1.2k
Yan Ren China	12	841 0.8×	588 1.5×	338 1.2×	114 0.6×	56 0.7×	30	1.0k
Ernesto Díaz-Flores United States	15	558 0.5×	305 0.8×	198 0.7×	153 0.8×	41 0.5×	29	859
Annette Orleth Italy	10	620 0.6×	403 1.0×	196 0.7×	81 0.4×	45 0.6×	14	843
Sarah Brennan United States	8	492 0.5×	308 0.8×	379 1.4×	136 0.7×	143 1.8×	12	801
Kimberly H. Harrington United States	11	343 0.3×	307 0.8×	492 1.8×	206 1.1×	55 0.7×	17	807
Trinayan Kashyap United States	19	756 0.7×	342 0.9×	234 0.8×	73 0.4×	35 0.4×	57	934
Maurizio Affer United States	11	571 0.6×	401 1.0×	176 0.6×	100 0.5×	83 1.1×	22	843
Meredith J. Taylor United States	6	1.8k 1.8×	775 2.0×	270 1.0×	117 0.6×	50 0.6×	11	2.0k
Luyao Xu China	5	628 0.6×	228 0.6×	180 0.6×	92 0.5×	38 0.5×	14	869
Kazumasa Aoyama Japan	20	791 0.8×	311 0.8×	133 0.5×	132 0.7×	49 0.6×	45	1.0k

Countries citing papers authored by Deanna A. Mele

Since Specialization

Citations

This map shows the geographic impact of Deanna A. Mele's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deanna A. Mele with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deanna A. Mele more than expected).

Fields of papers citing papers by Deanna A. Mele

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deanna A. Mele. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deanna A. Mele. The network helps show where Deanna A. Mele may publish in the future.

Co-authorship network of co-authors of Deanna A. Mele

This figure shows the co-authorship network connecting the top 25 collaborators of Deanna A. Mele. A scholar is included among the top collaborators of Deanna A. Mele based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deanna A. Mele. Deanna A. Mele is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Tay, Tristan, Gayathri Bommakanti, Aparna Gorthi, et al.. (2024). Degradation of IKZF1 prevents epigenetic progression of T cell exhaustion in an antigen-specific assay. Cell Reports Medicine. 5(11). 101804–101804. 4 indexed citations

Mele, Deanna A., Neil P. Grimster, Gayathri Bommakanti, et al.. (2023). Abstract 3453: First disclosure of a highly potent and selective HPK1 inhibitor that rescues T cell exhaustion. Cancer Research. 83(7_Supplement). 3453–3453. 3 indexed citations

Mele, Deanna A., et al.. (2022). Systemic nano-delivery of low-dose STING agonist targeted to CD103+ dendritic cells for cancer immunotherapy. Journal of Controlled Release. 345. 721–733. 51 indexed citations

Grimster, Neil P., Lisa Drew, Stephen E. Fawell, et al.. (2020). Abstract A56: Releasing the brake on T-cell activation through inhibition of HPK1. Cancer Immunology Research. 8(3_Supplement). A56–A56. 1 indexed citations

Chandra, Dinesh, Christine M. Barbon, Alexandra Borodovsky, et al.. (2020). Abstract A87: The A2AR antagonist AZD4635 prevents adenosine-mediated immunosuppression in tumor microenvironment and enhances antitumor immunity partly by enhancing CD103+ dendritic cells. Cancer Immunology Research. 8(3_Supplement). A87–A87. 2 indexed citations

Barbon, Christine M., Alexandra Borodovsky, Yanjun Wang, et al.. (2019). Abstract LB-192: The A2AR antagonist AZD4635 prevents adenosine-mediated immunosuppression of CD103+ dendritic cells. Cancer Research. 79(13_Supplement). LB–192. 3 indexed citations

O’Donovan, Daniel H., Yumeng Mao, & Deanna A. Mele. (2019). The Next Generation of Pattern Recognition Receptor Agonists: Improving Response Rates in Cancer Immunotherapy. Current Medicinal Chemistry. 27(34). 5654–5674. 16 indexed citations

Langdon, Sophie, Adina Hughes, Molly A. Taylor, et al.. (2018). Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity. OncoImmunology. 7(8). e1458810–e1458810. 40 indexed citations

Mele, Deanna A., Andrés Salmerón, Srimoyee Ghosh, et al.. (2013). BET bromodomain inhibition suppresses TH17-mediated pathology. The Journal of Experimental Medicine. 210(11). 2181–2190. 174 indexed citations

10.

Mertz, Jennifer A., Andrew R. Conery, Barbara M. Bryant, et al.. (2011). Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proceedings of the National Academy of Sciences. 108(40). 16669–16674. 876 indexed citations breakdown →

11.

Mele, Deanna A., et al.. (2011). Th17 differentiation is the default program for DPP2‐deficient T‐cell differentiation. European Journal of Immunology. 41(6). 1583–1593. 5 indexed citations

12.

Mele, Deanna A., et al.. (2009). Dipeptidyl Peptidase 2 is an essential survival factor in the regulation of cell quiescence. Cell Cycle. 8(15). 2425–2434. 20 indexed citations

13.

Danilova, Olga V., Albert Tai, Deanna A. Mele, et al.. (2009). Neurogenin 3-Specific Dipeptidyl Peptidase-2 Deficiency Causes Impaired Glucose Tolerance, Insulin Resistance, and Visceral Obesity. Endocrinology. 150(12). 5240–5248. 14 indexed citations

14.

Bista, Pradeep, et al.. (2008). Lymphocyte quiescence factor Dpp2 is transcriptionally activated by KLF2 and TOB1. Molecular Immunology. 45(13). 3618–3623. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact